Karyopharm Therapeutics (NASDAQ:KPTI) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.33) by 3.03 percent. This is a 6.67 percent decrease over losses of $(0.30) per share from the same period last year. The company reported quarterly sales of $33.126 million which missed the analyst consensus estimate of $34.473 million by 3.91 percent. This is a 14.40 percent decrease over sales of $38.698 million the same period last year.
Karyopharm Therapeutics Q1 2024 GAAP EPS $(0.32) Beats $(0.33) Estimate, Sales $33.126M Miss $34.473M Estimate
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.